The historical rank and industry rank for Apimeds Pharmaceuticals Us's PB Ratio or its related term are showing as below:
APUS'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.07
Current: 0.07
During the past 5 years, Apimeds Pharmaceuticals Us's highest PB Ratio was 0.07. The lowest was 0.00. And the median was 0.00.
APUS's PB Ratio is ranked better than 99.46% of 925
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs APUS: 0.07
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Apimeds Pharmaceuticals Us was -77.30% per year. The lowest was -77.30% per year. And the median was -77.30% per year.
Back to Basics: PB Ratio
Apimeds Pharmaceuticals Us (AMEX:APUS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Apimeds Pharmaceuticals Us PB Ratio Related Terms
Apimeds Pharmaceuticals Us PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apimeds Pharmaceuticals Us PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's PB Ratio distribution charts can be found below:
* The bar in red indicates where Apimeds Pharmaceuticals Us's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Apimeds Pharmaceuticals Us (APUS) has a PB Ratio of 0.07 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Apimeds Pharmaceuticals Us and its competitors. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #5 out of 925 companies in the Drug Manufacturers industry, placing it in the top 0.5%.
Is Apimeds Pharmaceuticals Us' PB Ratio too high?
Apimeds Pharmaceuticals Us' current PB Ratio is 0.07. The Drug Manufacturers industry median PB Ratio is 1.91. Apimeds Pharmaceuticals Us' value of 0.07 is 96.3% below this industry median. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #5 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' PB Ratio compare to KAYS and BIOE?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #5 out of 925 companies for PB Ratio. This places Apimeds Pharmaceuticals Us in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.91. Apimeds Pharmaceuticals Us' value of 0.07 is 96.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apimeds Pharmaceuticals Us's current PB Ratio of 0.07 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Apimeds Pharmaceuticals Us and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current PB Ratio is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current PB Ratio of 0.07. The current PB Ratio is 0.07 and 96.3% below the Drug Manufacturers industry median of 1.91. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current PB Ratio is 0.07 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score
Get the complete analysis for APUS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APUS has been successfully added to your 
